Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a global insulin delivery and diabetes technology company whose news flow centers on product innovation, regulatory milestones, financial performance, and corporate developments. The company manufactures and sells advanced automated insulin delivery systems, including the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology.
News updates for Tandem Diabetes Care often highlight regulatory and product announcements. Recent examples include FDA 510(k) clearance for the SteadiSet infusion set for up to seven days of use, FDA clearance for the Android version of the Tandem Mobi mobile app, and integration of the t:slim X2 pump with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the United States. The company also issues press releases on software and mobile app availability, such as the Tandem t:slim mobile app launch for Android and iOS users in Canada.
Investors and observers can also expect regular earnings and guidance updates. Tandem Diabetes Care reports quarterly financial results and provides full-year guidance, with related press releases and conference call details disclosed publicly. Additional news items cover corporate governance, such as the appointment of new board members and committee assignments, as well as certifications like ISO/IEC 27001:2022 for information security.
This news page for TNDM aggregates these types of announcements, including earnings releases, regulatory clearances, product compatibility updates, conference presentations, and technology rollouts. It provides a single location to follow how Tandem Diabetes Care’s insulin delivery systems, digital platforms, and global initiatives are evolving over time.
Tandem Diabetes Care (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, has announced its participation in three upcoming investor conferences in August and September 2025.
The company will present at the Canaccord Genuity Growth Conference on August 12 at 1:00 PM ET, the Morgan Stanley Global Healthcare Conference on September 10 at 9:15 AM ET, and will host meetings at the Bernstein Healthcare Forum on September 24. All presentations will be available via webcast on the company's investor relations website for 30 days.
Tandem Diabetes Care (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, has scheduled its second quarter 2025 financial results announcement for August 6, 2025 after market close.
The company will host a conference call and webcast at 4:30 PM Eastern Time on the same day to discuss the quarterly results. Investors can access the live webcast through Tandem's Investor Center website, with a recording available for 30 days afterward.
Tandem Diabetes Care (NASDAQ: TNDM), a leader in insulin delivery and diabetes technology, has announced its participation in three major upcoming investor conferences in May and June 2025:
- RBC Capital Markets Global Healthcare Conference on May 20, 2025 at 10:00am ET
- Jefferies Global Healthcare Conference on June 4, 2025 at 3:45pm ET
- Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025 at 8:40am ET
Management will present company updates at each conference. All presentations will be available via live webcast and archived for 30 days on Tandem's Investor Center website.
Tandem Diabetes Care reported strong Q1 2025 financial results, with worldwide sales growing 22% to $234.4 million. The company achieved record first-quarter performance, with U.S. pump sales increasing 19% and significant international growth.
Key highlights include:
- Worldwide pump shipments exceeded 28,000 units
- International sales reached $83.8 million
- U.S. sales showed robust growth with over 17,000 pump shipments
- 5-point improvement in adjusted EBITDA margin
- 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi
The company reaffirmed its 2025 guidance, projecting full-year sales between $997 million to $1.007 billion. Despite posting a GAAP net loss of $130.6 million, Tandem's non-GAAP metrics showed operational improvements, with gross margin reaching 51% compared to 49% in the previous year.
Tandem Diabetes Care (TNDM), a leading insulin delivery and diabetes technology company, has scheduled its first quarter 2025 financial results announcement for April 30, 2025, after market close.
The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss Q1 2025 financial and operating results. Investors can access the live webcast through Tandem's Investor Center website, and a recording will be available for 30 days afterward.
Tandem Diabetes Care (TNDM) announced positive results from its pivotal trial of Control-IQ+ automated insulin delivery technology for type 2 diabetes, published in The New England Journal of Medicine. The 13-week study showed significant improvements in glycemic control across a diverse population of 319 participants.
Key findings include:
- A1C reduction of 0.9% in Control-IQ+ group vs 0.3% in control group
- 2.3% A1C reduction in participants with baseline A1C ≥9%
- Time in range improved by 16%, adding 3.8 more hours/day in target range
- Insulin use decreased by 8 units/day in Control-IQ+ group
The study demonstrated effectiveness across diverse demographics, with 39% of participants from minority backgrounds. The technology proved safe with no new safety concerns, and received high usability scores regardless of participants' bolusing strategy.
Tandem Diabetes Care (NASDAQ: TNDM) has launched Control-IQ+ technology in the United States, an enhanced automated insulin delivery (AID) system now available for people with type 1 diabetes aged 2 years and older and adults with type 2 diabetes.
The new generation algorithm, compatible with both t:slim X2 insulin pump and Tandem Mobi System, offers expanded features including:
- Wider weight (20-440 lbs) and total daily insulin (5-200 units) parameters
- Enhanced extended bolus up to 8 hours with active Control-IQ+
- New Temp Basal Rate adjustments during active Control-IQ+
The technology is now shipping in pre-loaded pumps to new customers, while eligible in-warranty Tandem customers can access the update via free remote software update. The system maintains the company's unique AutoBolus™ feature, adjusting insulin every 5 minutes based on predicted glucose values.
Tandem Diabetes Care (TNDM) reported strong financial results for Q4 and full year 2024. Q4 worldwide GAAP sales grew 44% to $282.6M, with non-GAAP sales up 21% to $252.4M. Pump shipments increased by over 25% worldwide.
For full year 2024, worldwide GAAP sales rose 26% to $940.2M. The company achieved positive free cash flow and increased Tandem Mobi pump shipments throughout the year. Strategic highlights include FDA clearance for Control-IQ+ for type 2 diabetes and a multi-year collaboration with University of Virginia for closed-loop insulin delivery systems.
Looking ahead to 2025, TNDM projects full-year sales of $997M-$1.007B, with U.S. sales of $725M-$730M and international sales of $272M-$277M. Q1 2025 sales are estimated at $219M-$224M. The company expects a gross margin of approximately 54% for 2025.